Showing results (31-40 of 629) with videos related to
Sort By:
Pageof 63
Expert Review of Clinical Pharmacology|May 17, 2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendationsMattia Galli, Francesco Franchi, Fabiana Rollini, et al.Lancet (London, England)|April 18, 2021
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisMattia Galli, Stefano Benenati, Davide Capodanno, et al.Journal of Thrombosis and Thrombolysis|March 13, 2015
Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) studyFrancesco Pelliccia, Cesare Greco, Carlo Gaudio, et al.Clinical Pharmacokinetics|April 28, 2023
Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of BentracimabLuis Ortega-Paz, Salvatore Giordano, Francesco Franchi, et al.Minerva Cardiology and Angiology|October 23, 2023
Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapySalvatore Giordano, Francesco Franchi, Fabiana Rollini, et al.Expert Review of Clinical Pharmacology|July 11, 2017
Role of genetic testing in patients undergoing percutaneous coronary interventionJae Youn Moon, Francesco Franchi, Fabiana Rollini, et al.Drugs|July 29, 2024
Therapeutic Potential of FXI Inhibitors: Hype or Hope?Mattia Galli, Giovanni Occhipinti, Luis Ortega-Paz, et al.The American Journal of Cardiology|January 27, 2009
Variability in responsiveness to oral antiplatelet therapyDominick J AngiolilloDrugs|October 23, 2012
The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present dayDominick J AngiolilloAmerican Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 14, 2007
ADP receptor antagonism: what's in the pipeline?Dominick J AngiolilloPageof 63